Abbott Reports Xience Stent Launch Off To A Good Start
This article was originally published in The Gray Sheet
Executive Summary
Abbott says sales of its Xience V everolimus-eluting coronary stent during its first two weeks on the U.S. market have exceeded the company's pre-launch projections